Expression profiling of genes involved in paclitaxel biosynthesis for targeted metabolic engineering

Ezekiel Nims1, Camille P Dubois, Susan C Roberts

  • 1Plant Biology Graduate Program, University of Massachusetts, North Pleasant Street, Amherst, 01003, USA.

Metabolic Engineering
|June 24, 2006
PubMed

Insights

Methyl jasmonate (MJ) treatment boosts paclitaxel (Taxol) production in Taxus cell cultures by upregulating early pathway genes. This study identifies key gene expression patterns to enhance sustainable Taxol bioprocessing for cancer treatment.

Area of Science:

  • Plant Biotechnology
  • Metabolic Engineering
  • Cancer Therapeutics

Background:

  • Taxus plant cell cultures offer a sustainable source of paclitaxel (Taxol), a crucial anti-cancer drug.
  • Understanding the regulation of the taxane biosynthetic pathway is essential for optimizing paclitaxel production.

Purpose of the Study:

  • To investigate the gene expression profile of the paclitaxel biosynthetic pathway in Taxus cuspidata cell cultures.
  • To correlate gene expression with taxane metabolite levels following methyl jasmonate (MJ) elicitation.
  • To identify potential targets for metabolic engineering to increase paclitaxel accumulation.

Main Methods:

  • Utilized RNA gel blot analysis and RT-PCR to examine gene expression in Taxus cuspidata P991 cell line.
  • Measured taxane metabolite levels (paclitaxel, cephalomannine, 10-deacetylbaccatin III, baccatin III).
  • Applied methyl jasmonate (MJ) elicitation (100 microM) to induce pathway gene expression and metabolite accumulation.

Main Results:

  • MJ elicitation significantly increased paclitaxel and cephalomannine levels by day 7.
  • Early pathway genes (GGPPS, TASY, T5alphaH) were upregulated within 6-24 hours of MJ treatment.
  • Differential expression of pathway branches was observed, with higher abundance of TalphaH transcripts compared to TDAT and T10betaH.

Conclusions:

  • MJ elicits a specific early response in the taxane biosynthetic pathway, favoring certain branches.
  • Transcript levels of late-acting enzymes (BAPT, DBTNBT) were notably lower, suggesting potential bottlenecks.
  • Targeting these low-expressed terminal enzyme genes presents a promising strategy for enhancing paclitaxel yield in cell cultures.